TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques

Alice B. Gottlieb, Francesca Chamian, Salman Masud, Irma Cardinale, Maria Veronica Abello, Michelle A. Lowes, Fei Chen, Melissa Magliocco, James G. Krueger

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-γ-inducible protein-10 (CXCL10), and MIP-3α (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-γ, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.

Original languageEnglish (US)
Pages (from-to)2721-2729
Number of pages9
JournalJournal of Immunology
Volume175
Issue number4
StatePublished - Aug 15 2005
Externally publishedYes

Fingerprint

Psoriasis
Down-Regulation
Dendritic Cells
T-Lymphocytes
Lymphotoxin-alpha
Interleukin-8
Messenger RNA
Inflammation
Interleukin-23
Gene Expression
Granzymes
Immediate-Early Genes
Neutrophil Infiltration
Myeloid Cells
Interleukin-1
Keratinocytes
Chemokines
Nitric Oxide Synthase
Hyperplasia
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., ... Krueger, J. G. (2005). TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. Journal of Immunology, 175(4), 2721-2729.

TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. / Gottlieb, Alice B.; Chamian, Francesca; Masud, Salman; Cardinale, Irma; Abello, Maria Veronica; Lowes, Michelle A.; Chen, Fei; Magliocco, Melissa; Krueger, James G.

In: Journal of Immunology, Vol. 175, No. 4, 15.08.2005, p. 2721-2729.

Research output: Contribution to journalArticle

Gottlieb, AB, Chamian, F, Masud, S, Cardinale, I, Abello, MV, Lowes, MA, Chen, F, Magliocco, M & Krueger, JG 2005, 'TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques', Journal of Immunology, vol. 175, no. 4, pp. 2721-2729.
Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. Journal of Immunology. 2005 Aug 15;175(4):2721-2729.
Gottlieb, Alice B. ; Chamian, Francesca ; Masud, Salman ; Cardinale, Irma ; Abello, Maria Veronica ; Lowes, Michelle A. ; Chen, Fei ; Magliocco, Melissa ; Krueger, James G. / TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. In: Journal of Immunology. 2005 ; Vol. 175, No. 4. pp. 2721-2729.
@article{fdca81a401ab4dfca24e7f2118e20b09,
title = "TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques",
abstract = "The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-γ-inducible protein-10 (CXCL10), and MIP-3α (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-γ, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.",
author = "Gottlieb, {Alice B.} and Francesca Chamian and Salman Masud and Irma Cardinale and Abello, {Maria Veronica} and Lowes, {Michelle A.} and Fei Chen and Melissa Magliocco and Krueger, {James G.}",
year = "2005",
month = "8",
day = "15",
language = "English (US)",
volume = "175",
pages = "2721--2729",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques

AU - Gottlieb, Alice B.

AU - Chamian, Francesca

AU - Masud, Salman

AU - Cardinale, Irma

AU - Abello, Maria Veronica

AU - Lowes, Michelle A.

AU - Chen, Fei

AU - Magliocco, Melissa

AU - Krueger, James G.

PY - 2005/8/15

Y1 - 2005/8/15

N2 - The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-γ-inducible protein-10 (CXCL10), and MIP-3α (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-γ, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.

AB - The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-γ-inducible protein-10 (CXCL10), and MIP-3α (CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-γ, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.

UR - http://www.scopus.com/inward/record.url?scp=23444432216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444432216&partnerID=8YFLogxK

M3 - Article

VL - 175

SP - 2721

EP - 2729

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -